Affimed Therapeutics AG, an antibody engineering company, has changed the roles of the chief executive and chief commercial officer to accelerate development and partnering of its products under development.
Adi Hoess, the chief commercial officer, is now the chief executive and will oversee discussions with the pharmaceutical industry and business partners. Rolf Guenther, the chief executive, has become chief operating officer.
Affimed’s lead product is a bispecific, tetravalent human antibody specifically designed to treat Hodgkin Lymphoma. Phase 1 results are expected in 2012.
Copyright 2011 Evernow Publishing Ltd